Last updated: October 26, 2026
Olanzapine and fluoxetine hydrochloride is the fixed-dose combination marketed in the United States as Symbyax. Eli Lilly developed the product for depressive episodes associated with bipolar I disorder and for treatment-resistant depression. The product has lost the commercial advantages associated with branded exclusivity, and its market has shifted to low-cost generic competition. Lilly does not report Symbyax revenue as a separate line item, so current product-level sales and profitability cannot be established from public financial filings. [1][2]
What is olanzapine and fluoxetine hydrochloride used for?
Olanzapine and fluoxetine hydrochloride combines an atypical antipsychotic with a selective serotonin reuptake inhibitor.
| Attribute |
Details |
| Brand |
Symbyax |
| Active ingredients |
Olanzapine and fluoxetine hydrochloride |
| Originator |
Eli Lilly and Company |
| Dosage form |
Oral capsules |
| FDA approval |
2003 |
| Bipolar indication |
Acute depressive episodes associated with bipolar I disorder |
| Major depressive disorder indication |
Treatment-resistant depression in adults |
| Primary therapeutic categories |
Bipolar depression, major depressive disorder |
| FDA regulatory pathway |
New drug application |
| Current market structure |
Generic-dominated, with limited branded differentiation |
The combination is available in several strengths, including 3 mg/25 mg, 6 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg capsules. The product is distinct from prescribing olanzapine and fluoxetine as separate products because the fixed-dose capsule provides a single oral dosage form and a labeled combination indication. [2]
Olanzapine contributes antipsychotic activity through dopamine and serotonin receptor effects. Fluoxetine contributes antidepressant activity through serotonin reuptake inhibition. The combination was positioned for patients whose bipolar depression or treatment-resistant depression required both mechanisms.
When did Symbyax lose exclusivity?
Symbyax lost effective market exclusivity after the expiration of its principal product patents and the entry of generic olanzapine/fluoxetine capsules. The commercially important exclusivity period ended well before 2024.
| Milestone |
Approximate timing |
Commercial effect |
| FDA approval of Symbyax |
2003 |
Originator launch |
| Branded product protection period |
2000s to early 2010s |
Lilly controlled the combination market |
| First generic approvals and launches |
Early 2010s |
Price competition began |
| Loss of practical branded exclusivity |
Early-to-mid 2010s |
Symbyax prescriptions migrated to generics |
| Current market |
2024 onward |
Generic supply and reimbursement determine demand |
The original olanzapine patent estate did not preserve exclusivity for the fixed-dose combination through the 2020s. Generic applicants were able to rely on the abbreviated new drug application pathway after relevant listed patents expired or were addressed through patent certifications and litigation settlements.
The precise commercial launch dates varied by manufacturer and dosage strength. FDA approval records and the Orange Book, rather than Lilly’s financial statements, are the authoritative sources for product-specific generic approvals and listed patents. [3][4]
What patents protect olanzapine and fluoxetine hydrochloride?
The patent estate historically included three layers:
- Olanzapine compound patents.
- Fluoxetine compound and formulation patents.
- Fixed-dose combination and method-of-use patents covering the co-administration of olanzapine and fluoxetine.
The key commercial protection was the combination-product estate rather than the underlying molecule patents alone. Olanzapine and fluoxetine were both mature active ingredients when Symbyax launched, which limited the duration of new chemical matter protection for the combination.
Which patent types were commercially relevant?
| Patent category |
Protected subject matter |
Present commercial significance |
| Olanzapine compound patents |
Active antipsychotic compound |
Expired |
| Fluoxetine compound patents |
Active antidepressant compound |
Expired |
| Combination patents |
Co-formulated olanzapine and fluoxetine |
Expired or no longer a meaningful barrier to routine generic entry |
| Method-of-use patents |
Bipolar depression and treatment-resistant depression uses |
Limited ability to block unrestricted generic substitution |
| Manufacturing and formulation patents |
Capsule composition, dosage ratios, and production processes |
Potentially relevant to specific products, but not a broad market barrier |
Combination patents can delay generic entry if they are listed in the Orange Book and remain enforceable. Their value declines sharply when generic manufacturers can design around claim limitations, challenge validity, or launch after settlement dates.
A generic manufacturer does not need to infringe every historical patent associated with olanzapine or fluoxetine. It must address patents listed for the reference product and satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, labeling, and manufacturing quality.
What is the Orange Book status of Symbyax?
Symbyax is a drug product that has historically appeared in FDA Orange Book records with listed patents and exclusivity information. The Orange Book identifies approved products, therapeutic equivalence ratings, patent certifications, and exclusivity periods. [3]
The practical Orange Book position is now defensive rather than growth-oriented:
- The product’s main patents have expired or ceased to block ordinary generic substitution.
- Generic applicants can use the abbreviated new drug application pathway.
- Any remaining listed method-of-use patent would generally have narrower commercial reach than a composition patent.
- Prescription volume is exposed to automatic substitution and payer preference.
- The brand has limited leverage to maintain a premium absent a supply, contracting, or clinical differentiation.
Orange Book listings do not establish that a patent is valid or infringed. They identify patents submitted by the sponsor and the regulatory consequences of generic certifications. Patent enforceability remains a matter for litigation or settlement.
Which companies are challenging or competing with Symbyax?
The main competitive threat comes from generic manufacturers rather than from a single branded challenger.
Generic manufacturers
The generic market has included companies with established psychiatric-drug portfolios, including Teva Pharmaceuticals and other abbreviated new drug application holders. Product availability can differ by strength, manufacturer, pharmacy channel, and time period.
Generic competition operates through:
- lower acquisition cost;
- payer-preferred formulary placement;
- therapeutic equivalence;
- pharmacy-level substitution;
- multiple-source contracting.
Branded therapeutic competitors
Symbyax also competes clinically with separate drugs and other branded or generic therapies:
| Competitor |
Market position |
| Generic olanzapine plus generic fluoxetine |
Closest substitute, although prescribed as two products |
| Quetiapine |
Major bipolar depression competitor |
| Lurasidone |
Bipolar depression competitor |
| Cariprazine |
Bipolar depression and schizophrenia competitor |
| Lamotrigine |
Maintenance and bipolar depression treatment option |
| Antidepressants plus mood stabilizers |
Common treatment alternative in major depression and bipolar disorder |
| Olanzapine monotherapy |
Antipsychotic alternative without the fluoxetine component |
The fixed-dose combination retains a convenience advantage over two separate prescriptions. That advantage is weak when separate generic tablets are materially cheaper or when clinicians prefer independent dose titration.
What is the FDA regulatory status of olanzapine and fluoxetine?
The FDA-approved indications remain the central regulatory asset, but they do not create post-patent exclusivity. Symbyax was approved for:
- acute depressive episodes associated with bipolar I disorder; and
- treatment-resistant depression in adults.
The product carries clinically important warnings associated with olanzapine and fluoxetine. These include risks relating to metabolic changes, weight gain, hyperglycemia, dyslipidemia, tardive dyskinesia, neuroleptic malignant syndrome, and antidepressant-associated suicidality warnings in younger patients. Fluoxetine also has drug-interaction and serotonin-related risks. [2]
FDA approval of the combination does not prevent physicians from prescribing the individual generic components together. That substitution route reduces the strategic value of the fixed-dose formulation unless the capsule improves adherence or reimbursement.
How strong is the patent estate for olanzapine and fluoxetine?
The current patent estate is weak as a market-exclusion tool.
Strengths
- The combination had an FDA-approved indication distinct from many individual-component labels.
- Fixed-dose capsule patents could create technical barriers for specific formulations.
- Method-of-use claims could support targeted enforcement against a generic label.
- Product-specific patents may have delayed entry during the branded period.
Weaknesses
- The active ingredients are old, widely manufactured compounds.
- Core compound patents have expired.
- Generic manufacturers can use separate olanzapine and fluoxetine products as substitutes.
- Narrow combination claims are vulnerable to design-around strategies.
- Method-of-use patents have limited reach where generic labels use carve-outs.
- The product lacks a durable biologic or manufacturing-complexity barrier.
This is materially weaker than the estate surrounding a newly launched biologic, long-acting injectable, or complex drug-device product. The main remaining risks concern individual generic products, supply interruptions, formulation-specific patents, and litigation over a particular abbreviated new drug application.
What patent litigation and Paragraph IV risks affected Symbyax?
Generic applicants seeking early entry may file Paragraph IV certifications asserting that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger Hatch-Waxman litigation and a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions. [5]
For Symbyax, the principal litigation risk was concentrated in the period before generic entry. Once several generic manufacturers obtained approval and marketed the product, a single patent dispute had less ability to preserve the market.
| Risk category |
Impact on Symbyax |
| Paragraph IV challenge |
Could accelerate or delay generic entry |
| Patent litigation |
Important during the pre-generic period |
| Settlement agreement |
Could establish an agreed generic launch date |
| Label carve-out |
Could limit use of a generic for a patented indication |
| Multiple generic entrants |
Reduced the value of later litigation |
| Invalidity or noninfringement decision |
Could eliminate remaining entry barriers |
Publicly disclosed product-level financial filings do not provide a complete, consolidated record of every historical Symbyax Paragraph IV notice or settlement. The relevant litigation record must be matched by patent number, defendant, dosage strength, and filing date in federal court and FDA records.
What is the financial trajectory of Symbyax?
Lilly does not report Symbyax as a separately disclosed revenue product in its current annual reporting. The company aggregates many mature and smaller products into broader revenue categories. As a result, there is no reliable public series for annual Symbyax sales, operating margin, or current revenue exposure. [1]
The financial trajectory is nonetheless clear:
| Period |
Revenue profile |
Primary driver |
| 2003 to late 2000s |
Growth and branded pricing |
New indication and limited competition |
| Early 2010s |
Decline begins |
Generic entry and loss of exclusivity |
| Mid-2010s |
Sharp erosion |
Multiple-source generic competition |
| Late 2010s |
Mature low-value market |
Generic pricing and payer substitution |
| 2020s |
Limited brand relevance |
Generic supply, shortages, and prescription demand |
The product’s peak revenue was not disclosed separately by Lilly. Product-level estimates from commercial databases may differ because they measure prescriptions, pharmacy sales, or manufacturer revenue rather than net sales.
Lilly’s current financial exposure is therefore immaterial relative to its major growth products. Symbyax is no longer a meaningful driver of Lilly’s consolidated revenue, research spending, or valuation. The economic opportunity has shifted from branded lifecycle management to generic manufacturing and supply execution.
What generic launch scenarios exist?
Scenario 1: Continued generic erosion
This is the base case. Multiple approved suppliers keep prices low, and the brand retains a small residual share for prescriber or patient preference.
Scenario 2: Supply-driven price increases
If manufacturers discontinue one or more strengths, pharmacy acquisition costs could rise temporarily. Such increases would reflect supply concentration rather than restored patent exclusivity.
Scenario 3: Brand withdrawal with generic continuity
The branded product may become commercially unavailable while generic olanzapine/fluoxetine remains available. Clinical demand would continue through generic capsules or separate generic components.
Scenario 4: Separate-component substitution
Prescribers and payers may favor individual olanzapine and fluoxetine products because they permit independent titration and often carry lower costs. This is the strongest structural threat to the fixed-dose capsule.
How does Symbyax compare with other bipolar depression drugs?
| Factor |
Symbyax |
Quetiapine |
Lurasidone |
Cariprazine |
| Fixed combination |
Yes |
No |
No |
No |
| Generic availability |
Yes |
Yes |
Increasingly competitive |
More limited historically |
| Dose flexibility |
Lower than separate components |
Moderate |
Moderate |
Moderate |
| Weight and metabolic concerns |
Significant olanzapine-related risk |
Significant |
Generally lower than olanzapine |
Generally lower than olanzapine |
| Patent strength |
Weak or expired |
Mature |
Stronger during branded period |
Stronger during branded period |
| Commercial positioning |
Low-cost combination |
Broad bipolar and schizophrenia use |
Bipolar depression differentiation |
Bipolar depression differentiation |
Symbyax is most competitive when low cost, one-capsule administration, and an established indication outweigh concerns about metabolic adverse effects and limited dose flexibility.
Key Takeaways
- Olanzapine and fluoxetine hydrochloride is the generic version of Eli Lilly’s Symbyax.
- FDA approval covers bipolar I depressive episodes and treatment-resistant depression.
- Core compound and combination exclusivity has expired or no longer creates a meaningful market barrier.
- The Orange Book remains relevant for historical patent listings and generic certifications, but it does not indicate current commercial exclusivity.
- Generic manufacturers, including major multi-source suppliers, determine pricing and availability.
- Lilly does not separately disclose Symbyax revenue, so current product-level sales cannot be reliably quantified from public filings.
- The product’s financial trajectory moved from branded growth to generic erosion and now represents limited originator revenue exposure.
- The principal commercial risks are generic price competition, supply concentration, pharmacy substitution, and replacement by separate generic olanzapine and fluoxetine.
FAQs
Is olanzapine and fluoxetine hydrochloride the same as Symbyax?
Yes. Symbyax is the originator brand for the fixed-dose combination of olanzapine and fluoxetine hydrochloride.
Is there a generic for Symbyax?
Yes. Generic olanzapine and fluoxetine capsules are available through the FDA abbreviated new drug application pathway, although availability may vary by strength and manufacturer.
Can olanzapine and fluoxetine be prescribed separately?
Yes. Physicians can prescribe generic olanzapine and generic fluoxetine as separate products. This approach permits independent dose adjustment but eliminates the convenience of a single capsule.
Does Symbyax still have meaningful patent protection?
No broad, durable patent barrier appears to support branded market exclusivity in the 2020s. Any remaining product-specific or method-of-use rights would have narrower effects than the original combination estate.
Is Symbyax still financially important to Eli Lilly?
No. Lilly’s public reporting does not identify Symbyax as a material current revenue contributor. Its commercial importance is substantially below that of Lilly’s newer diabetes, obesity, oncology, and immunology products.
References
- Eli Lilly and Company. (2024). 2023 annual report. https://investor.lilly.com/financial-information/annual-reports
- U.S. Food and Drug Administration. (2024). Symbyax prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Content and format of an ANDA. https://www.fda.gov/drugs/guidance-compliance-regulatory-information-guidances-drugs/abbreviated-new-drug-application-anda-generics lodgement and patent certifications.
